Skip to content
← Survival collections

CANCER EVIDENCE

Conditional Survival

66 published cancer groups · 255,360 source series. Choose a group to explore its populations.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Source table

Published values for each cancer group are on that group page. This release supplies the source and dates.

Source
SEER
Table
Conditional Survival
Data submission
November 2025 submission
Application release
Updated
June 22, 2026
Acquired

Acute Lymphocytic Leukemia (ALL)

960 source series

→

Acute Monocytic Leukemia (AML-M5)

960 source series

→

Acute Myeloid Leukemia (AML)

960 source series

→

Adenocarcinoma of the Esophagus

4,800 source series

→

Adenocarcinoma of the Lung and Bronchus

4,800 source series

→

All Cancer Sites Combined

960 source series

→

Anus, Anal Canal & Anorectum

4,800 source series

→

Bones and Joints

4,800 source series

→

Brain and Other Nervous System

4,800 source series

→

Breast

3,200 source series

→

Cervix Uteri

1,600 source series

→

Chronic Lymphocytic Leukemia (CLL)

960 source series

→

Chronic Myeloid Leukemia (CML)

960 source series

→

Chronic Myelomonocytic Leukemia (CMML)

960 source series

→

Chronic myeloproliferative disorders (CMD)

960 source series

→

Colon (including Appendix)

4,800 source series

→

Colon and Rectum (excluding Appendix)

4,800 source series

→

Colon and Rectum (including Appendix)

4,800 source series

→

Corpus and Uterus, NOS

1,600 source series

→

Diffuse Astrocytoma and Anaplastic Astrocytoma of the Brain and ONS

4,800 source series

→

Embryonal Tumors of the Brain and ONS

4,800 source series

→

Esophagus

4,800 source series

→

Eye and Orbit

4,800 source series

→

Floor of Mouth

4,800 source series

→

Follicular Subtype of the Thyroid

4,800 source series

→

Gallbladder

4,800 source series

→

Glioblastoma of the Brain and ONS

4,800 source series

→

Gum & other mouth

4,800 source series

→

Hodgkin Lymphoma

4,800 source series

→

Kaposi Sarcoma

4,800 source series

→

Kidney

4,800 source series

→

Kidney and Renal Pelvis

4,800 source series

→

Large Cell Carcinoma of the Lung and Bronchus

4,800 source series

→

Larynx

4,800 source series

→

Leukemia

960 source series

→

Lip

4,800 source series

→

Liver and Intrahepatic Bile Duct

4,800 source series

→

Lung and Bronchus

4,800 source series

→

Melanoma of the Skin

4,800 source series

→

Meningioma of the Brain and ONS

4,800 source series

→

Mesothelioma

4,800 source series

→

Myelodysplastic syndromes (MDS)

960 source series

→

Myeloma

4,800 source series

→

Non-Hodgkin Lymphoma

4,800 source series

→

Oral Cavity and Pharynx

4,800 source series

→

Oropharynx & Tonsil

4,800 source series

→

Other Glioma of the Brain and ONS

4,800 source series

→

Ovary

1,600 source series

→

Pancreas

4,800 source series

→

Papillary Subtype of the Thyroid

4,800 source series

→

Prostate

1,600 source series

→

Rectum

4,800 source series

→

Renal Pelvis

4,800 source series

→

Salivary Gland

4,800 source series

→

Small cell carcinoma of the Lung and Bronchus

4,800 source series

→

Small Intestine

4,800 source series

→

Soft Tissue including Heart

4,800 source series

→

Squamous Cell Carcinoma of the Esophagus

4,800 source series

→

Squamous Cell Carcinoma of the Lung and Bronchus

4,800 source series

→

Stomach

4,800 source series

→

Testis

1,600 source series

→

Thyroid

4,800 source series

→

Tongue

4,800 source series

→

Urinary Bladder (Invasive & In Situ)

5,760 source series

→

Vagina

1,600 source series

→

Vulva

1,600 source series

→
Conditional Survival · SEER cancer survival | Triangle